BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Preclinical and clinical studies of immunotherapy in type 1 diabet
 es - Dr Frank Waldron-Lynch\, CIMR\, Cambridge
DTSTART:20130306T123000Z
DTEND:20130306T133000Z
UID:TALK41802@talks.cam.ac.uk
CONTACT:Sue Griffin
DESCRIPTION:Our aim is to further characterise the molecular basis for the
  autoimmune inflammatory disease type 1 diabetes.  We have used integrated
  combination of genetics\, in large collections of type 1 diabetic familie
 s and case/control\, statistics\, genome informatics and data mining\, and
  gene expression and immunological studies.  Our major effort now is to co
 rrelate susceptibility genotypes with biomarkers and phenotypes e.g. we ha
 ve associated flow cytometric phenotypes of T lymphocytes with disease-pre
 disposing genotypes of the IL-2RA (CD25) gene (Dendrou\, C. et al.  Nat. G
 enet. 41\, 1011-1015\, 2009).  This is a first step towards identifying di
 sease precursors that could be used in future therapeutic studies to strat
 ify patients.  To achieve this we have helped build a local biobank of vol
 unteers and type 1 diabetes patients in whom we can study the effects of d
 isease-associated genotypes and environmental factors (Cambridge BioResour
 ce: www.cambridgebioresource.org.uk/). \n\nThese immunology studies have u
 nderpinned the next major phase of our research: undertaking clinical stud
 ies with novel clinical trial design in patients with type 1 diabetes.  Ou
 r initial clinical trials will be to assess the effects and mechanisms of 
 ultra-low dose IL-2 on the immune system\, with a focus on T regulatory ce
 ll activities.  Our research efforts are part of the JDRF/Wellcome Trust D
 iabetes and Inflammation Laboratory (DIL)\, which has three other group le
 aders\, John Todd (Director) Linda Wicker (Co-director\, DIL)\, and Chris 
 Wallace (Head of Statistics group).\n
LOCATION:Lecture Theatre\, Department of Pathology\, Tennis Court Road
END:VEVENT
END:VCALENDAR